Galapagos triggers milestones of €2.5M in two of its strategic alliances

Genomics and drug discovery services company Galapagos NV, has triggered another milestone payment in its alliance with Janssen Pharmaceutica NV in rheumatoid arthritis, receiving a milestone payment of €1.5 million. To date, Galapagos has earned more than €24 million in payments from Janssen under this alliance.

At the same time the Mechelen, Belgium-based company said it had received a €1 million milestone payment under its alliance with GlaxoSmithKline, in infectious diseases. Since initiation of this deal at the end of 2007, Galapagos has received a total of €6 million.

“Galapagos continues to make progress across its strategic alliances, showing that our alliance model delivers strong growth in R&D revenues,” said Onno van de Stolpe, CEO of Galapagos.